Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and methods for treating anemia

An anemia and compound technology, applied in botany equipment and methods, drug combinations, active ingredients of heterocyclic compounds, etc., can solve problems such as increased expression of erythropoietin, decreased expression of hepatic antimicrobial peptide gene, and stimulation of erythropoietic activity

Inactive Publication Date: 2016-03-30
AKEBIA THERAPEUTICS
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0013] Under anemia or hypoxic conditions, not only the expression of erythropoietin is increased, which leads to the stimulation of erythropoietic activity, but also the expression of hepatic antimicrobial peptide gene is decreased at the same time

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for treating anemia
  • Compositions and methods for treating anemia
  • Compositions and methods for treating anemia

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0462] Pharmaceutical compositions may be employed in the preparation of a single unit dosage form. The pharmaceutical compositions and dosage forms provided herein comprise a compound as provided herein, or a pharmaceutically acceptable salt, solvate or hydrate thereof (eg, the parent compound). Pharmaceutical compositions and dosage forms may also contain one or more excipients.

[0463] In certain embodiments, pharmaceutical compositions and dosage forms comprise one or more excipients. Suitable excipients are well known to those skilled in the pharmaceutical arts, and non-limiting examples of suitable excipients are provided herein. Whether a particular excipient is suitable for incorporation into a pharmaceutical composition or dosage form depends on a variety of factors well known in the art including, but not limited to, the manner in which the dosage form will be administered to a patient. For example, oral dosage forms such as tablets may contain excipients which ar...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided herein are specific doses of, and dosing regimens for, using an HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.

Description

[0001] US Provisional Patent Application No. 61 / 834808 filed June 13, 2013; 61 / 889478 filed October 10, 2013; 61 / 898890 filed November 1, 2013; November 2013 61 / 898885, filed on 1 December; and 61 / 912185, filed December 5, 2013, each of which is incorporated herein by reference in its entirety. 1. Technical field [0002] The present disclosure relates to the use of HIF prolyl hydroxylase inhibitors in the treatment or prevention of anemia, such as anemia secondary to or associated with chronic kidney disease, anemia associated with or induced by chemotherapy, or associated with AIDS. Use in anemia. In addition, the present disclosure relates to HIF prolyl hydroxylase inhibitor compounds and pharmaceutically acceptable salts thereof, combinations comprising said HIF prolyl hydroxylase inhibitor compounds, and for use in the treatment or prevention of diseases, such as peripheral Methods for vascular disease (PVD), coronary artery disease (CAD), heart failure, ischemia, hypoxi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4439A61K31/345A01N43/40
CPCA61K31/4412A61K31/44A61P13/12A61P43/00A61P7/06A61K9/0053A61K33/26A61K38/1816A61K9/2054A61K9/2059A61K9/2077
Inventor 罗伯特·塞尔维茨夏洛特·哈特曼阿克沙伊·布赫艾塞亚·塞尔维茨约翰·雅努什约瑟夫·加德纳
Owner AKEBIA THERAPEUTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com